Pharmacokinetics, metabolism and drug-abuse potential of nabilone

https://doi.org/10.1016/S0305-7372(82)80031-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (9)

  • AgurellS. et al.

    Cannabinoids: metabolites hydroxylated in the pentyl side chain

  • BillingsR.E. et al.

    Steroselective enzymic-reduction of the synthetic 9-ketocannabinoid, nabilone, in vivo, in isolated liver cells and in liver homogenate

    Xenobiotica

    (1980)
  • LembergerL. et al.

    Metabolism and disposition of tetrahydrocannabinols in naive subjects and chronic marihuana users

    Ann. N.Y. Acad. Sci.

    (1971)
  • LembergerL. et al.

    11-Hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man

    Science

    (1972)
There are more references available in the full text version of this article.

Cited by (47)

  • The endocannabinoid system as a target for addiction treatment: Trials and tribulations

    2017, Neuropharmacology
    Citation Excerpt :

    Treatment with CB1 agonists could be used to reduce these signaling alterations and therefore suppress withdrawal symptoms. Three CB1 agonists have been studied: dronabinol, which is encapsulated oral Δ9-THC, nabilone, an oral synthetic analogue of Δ9-THC that exhibits dose linearity (Lemberger et al., 1982) and has a slower time to peak subjective effect than dronabinol (Bedi et al., 2013), and nabiximols, an oromucosal spray containing both Δ9-THC and CBD (Collin et al., 2007). A series of human laboratory trials have tested these three medications in non-treatment seeking cannabis users by employing designs in which individuals are instructed to smoke cannabis for one or more days and then abstain from use while receiving either CB1 agonist or placebo.

  • The synthetic analog of Δ<sup>9</sup>-tetrahydrocannabinol (THC): Nabilone. pharmacology and clinical application

    2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment
  • Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial

    2016, Drug and Alcohol Dependence
    Citation Excerpt :

    A possible solution might be to test nabilone, rather than dronabinol, as a treatment for cannabis use disorder. Notably, nabilone has better bioavailability (Ben Amar, 2006; Lemberger et al., 1982), is potent, and has shown little evidence of abuse (Haney et al., 2013; Lemberger et al., 1982). Further, ingestion of nabilone yields urinary metabolites that are unique from those produced from marijuana use; thus it can be differentiated from marijuana ingestion (Bedi et al., 2013; Fraser and Meatherall, 1989).

  • Separate and combined effects of the cannabinoid agonists nabilone and Δ <sup>9</sup>-THC in humans discriminating Δ <sup>9</sup>-THC

    2011, Drug and Alcohol Dependence
    Citation Excerpt :

    However, these discrepancies across studies can be associated with the development of tolerance to the performance-impairing effects of nabilone following multiple dose administrations (Frank et al., 2008; Kurzthaler et al., 2005), and cross-tolerance from regular use of cannabis (Lile et al., 2010a; present findings). Nabilone significantly increased heart rate, consistent with previous research (Glass et al., 1980; Lemberger et al., 1982; Lile et al., 2010a; Mendelson and Mello, 1984). Heart rate was elevated at the 3 mg dose of nabilone alone and when combined with certain doses of Δ9-THC, although worth noting is that the response to the drug combination was not dose dependent.

View all citing articles on Scopus
View full text